Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08CQY
|
|||
| Former ID |
DIB011764
|
|||
| Drug Name |
Brilacidin
|
|||
| Synonyms |
UNII-I1679X069H; 1224095-98-0; I1679X069H; Brilacidin [USAN:INN]; Brilacidin (USAN); SCHEMBL2878543; CHEMBL2219413; DTXSID90153594; AKOS030238222; DB12997; CS-6677; HY-19892; D10414; N,N'-Bis(3-((5-(carbamimidoylamino)pentanoyl)amino)-2-((3R)-pyrrolidin-3-yloxy)-5-(trifluoromethyl)phenyl)pyrimidine-4,6-dicarboxamide; 4,6-Pyrimidinedicarboxamide, N4,N6-bis(3-((5-((aminoiminomethyl)amino)-1-oxopentyl)amino)-2-((3R)-3-pyrrolidinyloxy)-5-(trifluoromethyl)phenyl)-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Acute bacterial skin infection [ICD-11: 1C41] | Phase 2 | [1] | |
| Infectious disease [ICD-11: 1A00-CA43.1; ICD-10: A00-B99] | Phase 2 | [2] | ||
| Company |
Cellceutix
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C40H50F6N14O6
|
|||
| Canonical SMILES |
C1CNCC1OC2=C(C=C(C=C2NC(=O)C3=CC(=NC=N3)C(=O)NC4=CC(=CC(=C4OC5CCNC5)NC(=O)CCCCN=C(N)N)C(F)(F)F)C(F)(F)F)NC(=O)CCCCN=C(N)N
|
|||
| InChI |
1S/C40H50F6N14O6/c41-39(42,43)21-13-25(57-31(61)5-1-3-9-53-37(47)48)33(65-23-7-11-51-18-23)27(15-21)59-35(63)29-17-30(56-20-55-29)36(64)60-28-16-22(40(44,45)46)14-26(34(28)66-24-8-12-52-19-24)58-32(62)6-2-4-10-54-38(49)50/h13-17,20,23-24,51-52H,1-12,18-19H2,(H,57,61)(H,58,62)(H,59,63)(H,60,64)(H4,47,48,53)(H4,49,50,54)/t23-,24-/m1/s1
|
|||
| InChIKey |
QPDYBCZNGUJZDK-DNQXCXABSA-N
|
|||
| CAS Number |
CAS 1224095-98-0
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Bacterial Cell membrane (Bact CM) | Target Info | Enhancer | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT02324335) Phase 2 Study to Evaluate the Safety & Efficacy of Brilacidin Oral Rinse in Patients With Head and Neck Cancer. U.S. National Institutes of Health. | |||
| REF 3 | Comparative mechanistic studies of brilacidin, daptomycin, and the antimicrobial peptide LL16. Antimicrob Agents Chemother. 2014 Sep;58(9):5136-45. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.